4-Piperidinamine,1-acetyl-N-methyl-N-[[(trans-4-phenylcyclohexyl)amino]carbonyl]- | 494861-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Piperidinamine,1-acetyl-N-methyl-N-[[(trans-4-phenylcyclohexyl)amino]carbonyl]-
• CAS: 494861-07-3
• 化学式: C₂₁H₃₁N₃O₂
• 分子量: 357.496
• InChiKey: YXJVHGRECXOLSW-WGSAOQKQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.37
• 重原子数：
  26.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  52.65
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  、 乙酸酐 在 三乙胺 作用下， 生成 4-Piperidinamine,1-acetyl-N-methyl-N-[[(trans-4-phenylcyclohexyl)amino]carbonyl]-
  参考文献：
  名称：

  Discovery of novel orally active ureido NPY Y5 receptor antagonists

  摘要：

  We have derived a novel series of neuropeptide Y (NPY) Y5 receptor antagonists from the biphenylurea 3. Cyclohexylurea 21c, a member of the series, is a potent NPY Y5 receptor antagonist that exhibits excellent pharmacokinetic parameters in rats and dogs. On chronic oral administration to diet-induced obese rats, 21c displayed an anti-obesity profile, causing a modest reduction in food intake, a significant decrease in body weight gain, a decrease in adipose mass, and an increase in lean tissue mass. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.132

文献信息

• US7304076B2
  申请人：——

  公开号：US7304076B2

  公开（公告）日：2007-12-04
• Discovery of novel orally active ureido NPY Y5 receptor antagonists
  作者：Guoqing Li、Andrew W. Stamford、Ying Huang、Kuo-Chi Cheng、John Cook、Constance Farley、Jun Gao、Lorraine Ghibaudi、William J. Greenlee、Mario Guzzi、Margaret van Heek、Joyce J. Hwa、Joe Kelly、Deborra Mullins、Eric M. Parker、Sam Wainhaus、Xiaoping Zhang

  DOI：10.1016/j.bmcl.2007.11.132

  日期：2008.2

  We have derived a novel series of neuropeptide Y (NPY) Y5 receptor antagonists from the biphenylurea 3. Cyclohexylurea 21c, a member of the series, is a potent NPY Y5 receptor antagonist that exhibits excellent pharmacokinetic parameters in rats and dogs. On chronic oral administration to diet-induced obese rats, 21c displayed an anti-obesity profile, causing a modest reduction in food intake, a significant decrease in body weight gain, a decrease in adipose mass, and an increase in lean tissue mass. (C) 2007 Elsevier Ltd. All rights reserved.